Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 14720331 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | prostate cancer | NA | NA | NA | unclassified | |
| to evaluate the safety and toxicity of peptide vaccination for patients with metastatic hormone-refractory prostate cancer (hrpc) based on pre-existing peptide-specific cytotoxic t-lymphocyte (ctl) precursors in the circulation, 10 patients positive for human leukocyte antigen (hla)-a2 with metastatic hrpc were enrolled in a phase i study. | |||||||
| 14997204 | HLA-A*02 | prostate cancer | NA | NA | NA | only_studied | |
| identification of an hla-a*0201-restricted t-cell epitope derived from the prostate cancer-associated protein prostein. | |||||||
| 15129427 | HLA-A*24 | phosphate | NA | estramustine | NA | unclassified | |
| NA | |||||||
| 15129427 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | phosphate | NA | estramustine | NA | unclassified | |
| NA | |||||||
| 15176050 | HLA-A*24 | prostate cancer | NA | NA | NA | unclassified | |
| a prostate stem cell antigen-derived peptide immunogenic in hla-a24- prostate cancer patients. | |||||||
| 15176050 | HLA-A*24 | prostate cancer | NA | NA | NA | unclassified | |
| we attempted to identify prostate stem cell antigen (psca)-derived peptides immunogenic in hla-a24+ prostate cancer patients. | |||||||
| 15176050 | HLA-A*24 | prostate cancer | NA | NA | NA | unclassified | |
| among three psca peptides, the psca 76-84 peptide most effectively induced peptide-specific cytotoxic t lymphocytes (ctls) from pbmcs of hla-a24+ prostate cancer patients. | |||||||
| 15176050 | HLA-A*24 | prostate cancer | NA | NA | NA | positive | |
| the psca 76-84 peptide-stimulated pbmcs showed a significant level of cytotoxicity against prostate cancer cells in an hla-a24-restricted manner. | |||||||
| 15289844 | HLA-A*02 | prostate cancer | NA | NA | NA | unclassified | |
| prostate-related antigen-derived new peptides having the capacity of inducing prostate cancer-reactive ctls in hla-a2+ prostate cancer patients. | |||||||
| 15289844 | HLA (HLA) | prostate cancer | NA | NA | NA | unclassified | |
| in this study, we attempted to newly identify epitope peptides from these 2 antigens, which are immunogenic in human histocompatibility leukocyte antigen (hla)-a2+ prostate cancer patients. | |||||||
Copyright 2024